Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy.

Fondazione IRCCS Istituto Neurologico, Milan, Italy.

Survival: monthsCountry:Italy
Toxiciy Grade:4City/State/Province:Milan
Treatments:ChemotherapyHospital:Fondazione IRCCS Istituto Neurologico
Drugs:Journal:Link
Date:Jun 2007

Description:

Patients: This phase II trial involved 54 patients with glioblastoma multiforme. The patients ranged in age from 26 to 68 years old, with a median age of 53.5 years. The majority (75.9%) of patients were men. They had all received temozolomide.

Treatment: The patients received the chemotherapy drugs procarbazine and fotemustine.
Fotemustine is cytotoxic (it kills cells) and procarbazine slows or stops the growth of tumor cells by damaging DNA and RNA.

Toxicity: One patient developed deep vein thrombosis and another developed pneumonia (both grade 3). Grade 3 liver toxicity occurred in two patients. Grade 2 nausea and vomiting occurred in five patients. Grade 4 neutropenia and thrombocytopenia were reported in four and two patients, respectively.

Results: The median overall survival of these patients was 20.8 months from the time of first diagnosis. The median survival from the time of starting this treatment regimen was 28.7 weeks.

Correspondence: Dr. Antonio Silvani



Back